Inventor · disambiguated record
Randy J. Chandler
Also filed as: CHANDLER RANDY · CHANDLER RANDY J
8 granted patents·8 pending applications·26 citations·filing 2009–2024
82Inventor score
Files withUS HEALTH10VENDITTI CHARLES P2LOGICBIO THERAPEUTICS INC1THE UNITED STATE OF AMERICA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES1THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVI1
Top patents by PatentIndex Score
16 records- 0191US9944918B2Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)US HEALTH·Filed 2016·Granted Apr 17, 2018·9 cites·11 claims
- 0291US9719080B2Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)US HEALTH·Filed 2014·Granted Aug 1, 2017·9 cites·18 claims
- 0386US10307469B2Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)US HEALTH·Filed 2017·Granted Jun 4, 2019·3 cites·11 claims
- 0480US2025161383A1Viral gene therapy as treatment for cholesterol storage disease or disorderTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVI·Filed 2024·Application pending·0 cites
- 0574US2024409948A1Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditionsUS HEALTH·Filed 2024·Application pending·0 cites
- 0671US8293187B2Device and method for direct measurement of isotopes of expired gasesVENDITTI CHARLES P·Filed 2009·Granted Oct 23, 2012·5 cites·17 claims
- 0770US10894077B2Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)US HEALTH·Filed 2019·Granted Jan 19, 2021·0 cites·33 claims
- 0869US12201658B2Viral gene therapy as treatment for cholesterol storage disease or disorderUS HEALTH·Filed 2020·Granted Jan 21, 2025·0 cites·13 claims
- 0960US2025049952A1Improved gene therapy constructs for the treatment of propionic acidemia caused by mutations in propionyl-coa carboxylase alphaUS HEALTH·Filed 2022·Application pending·0 cites
- 1056US2023383278A1Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiencyVENDITTI CHARLES P·Filed 2021·Application pending·0 cites
- 1154US12116577B2Codon-optimized human NPC1 genes for the treatment of Niemann-Pick type C1 deficiency and related conditionsTHE UNITED STATE OF AMERICA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES·Filed 2018·Granted Oct 15, 2024·0 cites·11 claims
- 1254US2022325266A1Synthetic genes for the treatment of propionic acidemia caused by mutations in propionyl-coa carboxylase betaUS HEALTH·Filed 2020·Application pending·0 cites
- 1350US11447797B2AAV with unique capsid protein VP1 and methods of using for treatmentUS HEALTH·Filed 2016·Granted Sep 20, 2022·0 cites·12 claims
- 1448US2022251536A1Synthetic genes for the treatment of propionic acidemia caused by mutations in propionyl-coa carboxylase alphaUS HEALTH·Filed 2020·Application pending·0 cites
- 1541US2022218843A1Non-disruptive gene therapy for the treatment of mmaLOGICBIO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1641US2018104289A1Viral gene therapy as treatment for cholesterol storage disease or disorderTHE US SECRETARY OF HEALTH AND HUMAN SERVICES·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →